Lumizyme approved for Pompe disease - ONA
Links shared publicly online about this topic.
- 1,142total visits
Lumizyme approved for Pompe disease - ONA
View full resource at oncologynurseadvisor.com
Tags: Heart, Disease and Condition, FDA, Genzyme, disease
Most Recently Shared on May 25, 2010 at 8:42 pm By:
Lumizyme approved for Pompe disease http://goo.gl/fb/sTmoX
Physician's Weekly Article - Treatment Approved for Late-Onset Pompe Disease
physweeklyarchives.com — “Physician's Weekly, your source for medical news, information on new drugs and devices, clinical updates, CME accreditation for radiology, emergency medicine, pediatrics, mammography, and anesthesia .” View full resource at physweeklyarchives.com
Most Recently Shared on August 26, 2010 at 9:29 pm By:
Treatment Approved for Late-Onset Pompe Disease - The FDA has approved alglucosidase alfa (Lumizyme, Genzyme Corp.) ... http://ow.ly/18JYcf
UF administers Lumizyme for late-onset Pompe disease
news-medical.net — “The first commercially available treatment in the United States for patients with late-onset Pompe disease was administered Wednesday, June 16, at the University of Florida.” View full resource at news-medical.net
Most Recently Shared on June 18, 2010 at 7:45 am By:
UF administers Lumizyme for late-onset Pompe disease: The first commercially available treatment in the United Sta... http://bit.ly/bU5ITz
Lumizyme Approved for Non-Infantile Pompe Disease --Doctors Lounge
doctorslounge.com — “Lumizyme Approved for Non-Infantile Pompe Disease --Doctors Lounge” View full resource at doctorslounge.com
Most Recently Shared on May 29, 2010 at 4:24 am By:
Lumizyme Approved for Non-Infantile Pompe Disease: A rare genetic disorder http://bit.ly/bDe1si
FDA Approves Lumizyme for Late-Onset Pompe Disease
drugs.com — “Lumizyme (alglucosidase alfa) is used to treat Pompe disease. Includes Lumizyme side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on May 28, 2010 at 8:31 am By:
FDA Approves Lumizyme for Late-Onset Pompe Disease - http://bit.ly/avpJ9U
FDA approves drug for late-onset Pompe disease - Related Stories - AAP SmartBrief
smartbrief.com — “The FDA granted marketing approval for Genzyme's drug Lumizyme for patients age 8 and older with non-infantile Pompe disease. The agency said Lumizyme will be sold with a boxed warning on its label about potential adverse effects, including severe allergic reaction and anaphylaxis. <a href='/servlet” View full resource at smartbrief.com
Most Recently Shared on May 27, 2010 at 4:23 am By:
Clara Song Pediatrician, Physician, and Doctor
FDA approves drug for late-onset Pompe disease http://sbne.ws/r/4MR9
New treatment approved for children with late-onset Pompe's disease
pediatricsupersite.com — “The FDA has approved alglucosidase alfa for children aged 8 years and older who have late-onset Pompe’s disease, a rare genetic disorder” View full resource at pediatricsupersite.com
Most Recently Shared on May 26, 2010 at 8:09 pm By:
Pediatric SuperSite Health Site
New treatment approved for children with late-onset Pompe’s disease: http://ow.ly/1Qkif
Lumizyme receives FDA approval for patients with late-onset Pompe disease
news-medical.net — “The U.S. Food and Drug Administration approved Lumizyme (alglucosidase alfa) for patients ages 8 years and older with late-onset (non-infantile) Pompe disease, a rare genetic disorder.” View full resource at news-medical.net
Most Recently Shared on May 26, 2010 at 9:19 am By:
Stroke News: Lumizyme receives FDA approval for patients with late-onset Pompe disease: The U.S. Food and Drug A... http://twurl.nl/18htwo
Lumizyme approved for Pompe disease - MPR
empr.com — “Genzyme announced the FDA approval of Lumizyme (alglucosidase alfa), a lysosomal glycogen-specific enzyme, for the treatment of patients 8 years of age with late (non-infantile) onset Pompe disease (acid -glucosidase (GAA) deficiency) who do not have evidence of cardiac hypertrophy” View full resource at empr.com
Most Recently Shared on May 25, 2010 at 5:44 pm By:
Lumizyme approved for Pompe disease: Genzyme announced the FDA approval of Lumizyme (alglucosidase alfa), a lysoso... http://bit.ly/c4DNLj
Lumizyme approved for Pompe disease - MPR
empr.com — “Genzyme announced the FDA approval of Lumizyme (alglucosidase alfa), a lysosomal glycogen-specific enzyme, for the treatment of patients 8 years of age with late (non-infantile) onset Pompe disease (acid -glucosidase (GAA) deficiency) who do not have evidence of cardiac hypertrophy” View full resource at empr.com
Most Recently Shared on May 25, 2010 at 5:40 pm By:
MPR News: Lumizyme approved for Pompe disease: Genzyme announced the FDA approval of Lumizyme (alglucosidase alfa)... http://bit.ly/d9RDQi
FDA Approves New Treatment for Late-Onset Pompe Disease | Earth Times News
earthtimes.org — “FDA Approves New Treatment for Late-Onset Pompe Disease | Earth Times News” View full resource at earthtimes.org
Most Recently Shared on May 25, 2010 at 2:59 pm By:
John Carroll Health Communicator
RT @adamfeuerstein: $GENZ -- FDA approved lumizyme for pompe disease. This is surprisingly early. >> PR: http://bit.ly/avDG4N
UPDATE 2-Genzyme's Pompe drug rejected--new production woes | Reuters
reuters.com — “* FDA rejects Genzyme's Pompe disease drug * Cites deficiencies at manufacturing plant in Boston * Shares up as shipping still on track (Updates with details from company conference call) By Toni” View full resource at reuters.com
Most Recently Shared on November 16, 2009 at 5:29 pm By:
Genzyme says FDA declines to approve Pompe disease drug - Reuters http://ow.ly/1623UI
FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial
news-medical.net — “ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.” View full resource at news-medical.net
Most Recently Shared on October 15, 2009 at 1:01 am By:
Genetics News: FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial: ZyStor Th.. http://buzzup.com/ffcp
Advertisement
